BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  RSV Race Rounds the Corner with Big Pharmas Neck and Neck

  Pfizer, J&J and GSK indicate plans to file for regulatory approval by the end of this year for vaccines against RSV, which would see vaccines against the disease becoming available in 2023.

  April 15, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Regeneron’s COVID-19 Therapy Hits Delay as AstraZeneca Racks Up Another Victory

  Regeneron announced that the U.S. FDA has extended its review of the BLA for monoclonal antibody REGEN-COV, which treats COVID-19.

  April 15, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  TG Therapeutics Backpedals on BLA for Lymphoma, Leukemia Treatment

  TG Therapeutics voluntarily withdrew its pending BLA and supplemental NDA for its treatment dubbed U2 for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

  April 15, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  BMS and Nektar Shutter Combination Cancer Development Program

  Bristol Myers Squibb and Nektar Therapeutics ended their global clinical program for potential bladder cancer and renal cell carcinoma treatment.

  April 15, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  FDA Grants EUA for COVID-19 Breathalyzer

  The U.S.Food and Drug Administration has granted Emergency Use Authorization to a breathalyzer that can detect COVID-19 within three minutes.

  April 15, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  McKinsey & Co. Under Fire for Allegedly Advising Purdue and FDA Concurrently

  McKinsey & Company is under fire for allegedly allowing its employees to work simultaneously for big pharma companies and serve as consultants for the U.S. Food and Drug Administration.

  April 15, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Clinical Catch-Up: AACR, AAN and COVID-19

  It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.

  April 15, 2022

   · 

  12 min read

   · 

  Mark Terry
• 

  Drug Development

  CG Oncology’s Bladder Cancer Therapy Impresses at AACR

  CG Oncology presented positive interim Phase II results for its Core1 trial studying the use of CG0070 at the American Association for Cancer Research (AACR) Annual Meeting.

  April 15, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Multiple Sclerosis Economic Burden hits $85 Billion as Treatments Advance

  There are an estimated 2.3 million people living with Multiple Sclerosis and hundreds of thousands more undiagnosed, adding up to an annual cost of nearly $85 billion for care in the United States.

  April 15, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology

  BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.

  April 15, 2022

   · 

  6 min read

   · 

  Gail Dutton